Stanley Friedman

Array ( [id] => 17720392 [patent_doc_number] => 20220213112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/547779 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685834 [patent_doc_number] => 20220193126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => METHODS OF TREATING IMBALANCE OF PLASMA LIPIDS LEVEL AND FATTY LIVER WITH M2C MACROPHAGES [patent_app_type] => utility [patent_app_number] => 17/545614 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117485 [patent_doc_number] => 11548866 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-10 [patent_title] => Therapeutic compounds and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/532698 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18900 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893680 [patent_doc_number] => 20240009165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => GRISEOFULVIN AS AN ADJUNCT DRUG FOR THE TREATMENT OF CEREBRAL AND SEVERE MALARIA [patent_app_type] => utility [patent_app_number] => 18/253744 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860133 [patent_doc_number] => 20230414567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/250596 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581548 [patent_doc_number] => 20230263800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION [patent_app_type] => utility [patent_app_number] => 18/043303 [patent_app_country] => US [patent_app_date] => 2021-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20218 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482082 [patent_doc_number] => 20220089586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => NLRX1 LIGANDS [patent_app_type] => utility [patent_app_number] => 17/479337 [patent_app_country] => US [patent_app_date] => 2021-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 311 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17479337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17784625 [patent_doc_number] => 11407737 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-09 [patent_title] => Inhibitors of RAF kinases [patent_app_type] => utility [patent_app_number] => 17/477260 [patent_app_country] => US [patent_app_date] => 2021-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44913 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 915 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18133876 [patent_doc_number] => 11559525 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Therapeutic drug for dyskinesia [patent_app_type] => utility [patent_app_number] => 17/461015 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 36 [patent_no_of_words] => 28523 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18314109 [patent_doc_number] => 11628169 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Therapeutic drug for motor complications in Parkinson's disease [patent_app_type] => utility [patent_app_number] => 17/461024 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 47 [patent_no_of_words] => 51939 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511304 [patent_doc_number] => 20230227442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => HETEROALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/009689 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19121013 [patent_doc_number] => 11964983 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Selective CDK4/6 inhibitor cancer therapeutics [patent_app_type] => utility [patent_app_number] => 18/008636 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5990 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18484862 [patent_doc_number] => 20230212171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/000722 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 563 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468778 [patent_doc_number] => 20230203060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/927961 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 159098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 3693 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126133 [patent_doc_number] => 20210300901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/331015 [patent_app_country] => US [patent_app_date] => 2021-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17331015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18435943 [patent_doc_number] => 20230183237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 [patent_app_type] => utility [patent_app_number] => 17/998901 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 455 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724173 [patent_doc_number] => 20230338294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => NOVEL PHARMACEUTICAL FORMULATION FOR C-MET INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/997126 [patent_app_country] => US [patent_app_date] => 2021-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17004539 [patent_doc_number] => 20210235700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => ANTIMICROBIAL COMPOSITIONS WITH ENHANCED EFFICACY [patent_app_type] => utility [patent_app_number] => 17/301618 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13034 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18374432 [patent_doc_number] => 20230149511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => TREATING AUTOIMMUNE DISEASES WITH GENETICALLY MODIFIED CELLS [patent_app_type] => utility [patent_app_number] => 17/995847 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582944 [patent_doc_number] => 20230265202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => ANTIBODY CONSTRUCTS BINDING 4-1BB AND FOLATE RECEPTOR ALPHA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/919109 [patent_app_country] => US [patent_app_date] => 2021-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -94 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17919109 [rel_patent_id] =>[rel_patent_doc_number] =>)